Vun-Sin Lim, PhD

#WCLC25 It takes a village! Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @IASLC! @DrAlexAdjei @JTOonline @ElsevierConnect #JTO #JTOCRR

Our review on targeting MET in EGFRm NSCLC is out in @JTOonline! Always interesting to appreciate the similar challenges we face treating EGFRm lung cancer around the world. Thanks to all my co-authors, academia is much better with friends indeed ☺️

Should we do molec testing on all NSCLCs? Answer: YES @JTOonline - 82328pts - 35.1% AGA+ (adeno=45.8% adenosq=40.9% sarcomatoid=29.1% NOS=27.6%, LCC=21.1% sq=6.5%) - age, sex, region assoc seen Congrats @Al3ssandroRusso @ChristianRolfo @oncoalert #LCSM jto.org/article/S1556-…

Celebrating Young-Tae Kim for his role as JTO Associate Editor since 2013. Your contributions to the Journal are deeply appreciated. #JTO20

Durvalumab after CRT in LS-SCLC… consistency everywhere 🔥 ADRIATIC subset analysis shows OS benefit across all key subgroups: ▪️ Cisplatin & carboplatin ▪️ QD & BID RT ▪️ PCI & no PCI 👉 No matter how you delivered cCRT, durvalumab seems to add benefit. A reassuring signal for real-world practice where treatment approaches vary. ⚠️ Still, these are non-randomized subgroup comparisons — interpret differences (e.g. carbo or BID looking better) with caution. @OncoAlert @OncoReporte @MedwatchKate @LungSummit @MedicalwatchHQ @IFCTlung @brunolarvol @lung_connect @Lung_Cancers 👉 jto.org/article/S1556-…

Honoring Rafal Dziadziuskzko, who served as JTO Associate Editor from 2013 to 2022. Thank you for helping shape the journal. #JTO20

Report @JTOonline notes intestinal lymphangiectasia seen in 29% of patients with RET fusion positive NSCLC treated with selpercatinib or pralsetinib. Incidence at 1y was 11%, 3y = 27%, 5y = 31% with greater risk if prior immunotherapy. Median onset 15m. jto.org/article/S1556-…

Subset data from ADRIATIC @JTOonline. Consolidation durvalumab after chemoradiation in LS-SCLC improved OS across subsets: cisplatin (HR 0.82) and carboplatin (HR 0.56); daily XRT (HR 0.72) and bid (HR 0.68); PCI (HR 0.75) and no PCI (HR 0.71). jto.org/article/S1556-…

Thank you to Dirk de Ruysscher, former Associate Editor of JTO for your 11 years of service supporting scientific excellence. #JTO20

MTAP deletions co-occur with CDKN2A loss in a subset of #NSCLC and are linked to poorer outcomes. @JessieStuart316 et al. highlight potential targeting strategies using PRMT5 and MAT2A inhibitors via synthetic lethality. Read now: bit.ly/47hg8ps #LungCancer

Our paper is online @JTOonline Molecular Profiling across 80,000 Patients with Lung Cancer. A robust demonstration that we need to test all patients with NSCLC & ALL histologies and open the door for nomenclature change. jto.org/article/S1556-… @Al3ssandroRusso @OhioStateMedOnc

A strong showing of the next generation at #ELCC26. @DrAlexAdjei, EIC of @JTOonline and IASLC President-Elect, joined by @pompili_cecilia, spoke to an attentive audience of young oncologists this morning.

Proud to be co-1st author on this new ATORG consensus on ctDNA MRD in early-stage NSCLC in @JTOonline ! Congrats to Aaron for leading it. Great celebrating our achievement over lunch today #JSMO26! @mollylisc @danieltanmd @drdaviddwlee @TonyMok9 #LCSM jto.org/article/S1556-…

.@MartinReck2 et al. report results from EVOKE-02. SG + pembrolizumab showed encouraging activity in #mNSCLC, particularly in patients with PD-L1 TPS ≥50%, with a safety profile consistent with each agent. Read now: bit.ly/47RRuf5 #LungCancer #ThoracicOncology

March JTO Editor’s Choice: Zhu et al. Explore a new IASLC review tackling complex, locally advanced #NSCLC scenarios commonly discussed in multidisciplinary tumor boards, offering practical insights for real-world decision-making. Read now: bit.ly/4rPk5sT

More immunotherapy disappointment in EGFR mutant NSCLC. Results from ORCHARD cohort of durvalumab + chemo after 1L osimertinib @JTOonline showed RR only 16%, PFS only 4.8m. Better options would be amivantamab + chemo, osi + chemo, dato-DXd / ADCs. jtocrr.org/article/S2666-…

Phase Ib TROPION-Lung02 Trial of 1L datopotamab deruxtecan (TROP2 ADC) + pembro +/- platinum in NSCLC @JTOonline. Dato-DXd + pembro: RR 55%, DOR 20m, PFS 11m. Dato + pembro + plat: RR 56%, DOR 14m, PFS 7m with more AEs. Phase III AVANZAR trial underway. jto.org/article/S1556-…

Recognizing Keith Kerr, Associate Editor of JTO (2013-present). We appreciate your continuing contributions to the Journal! #JTO20

📢 JTO Fun Fact 4,000+ citations and counting. The IASLC/ATS/ERS classification of lung adenocarcinoma (Travis, Brambilla, Noguchi et al.) is the most cited article in JTO history. Read more: bit.ly/4uDPRvy #JTO20

🎉As JTO marks a major milestone, Associate Editor Luis M. Montuenga, serving since 2012, reflects on the journal’s journey and impact. Thank you, Luis, for your leadership and dedication! #JTO20

What happens to pts with resectable NSCLC who don’t make it to surgery after neoadjuvant chemo-immunotherapy?@JTOonline In this multicenter study (n=57), definitive RT is a valid alternative: 👉 1-year OS 81% 👉 mPFS 16.1 mo 👉 Pneumonitis 18% 🔬 pubmed.ncbi.nlm.nih.gov/41852936/